Shinichiro Ueda's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q1 2025
Question
Shinichiro Ueda from Goldman Sachs asked about Takeda's launch preparations for oviporexant, specifically regarding the commercial team structure and the use of digital technologies to improve patient diagnosis for narcolepsy type 1.
Answer
U.S. Business Unit President Julie Kim confirmed that Takeda is actively preparing for the launch, with medical teams already educating in the field. She highlighted a focus on using multiple digital avenues to support and unlock bottlenecks in diagnosis, particularly through sleep centers, with more details to be shared closer to launch.